可溶性程序性细胞死亡 - 配体1的治疗前血清水平预测乙型肝

StephenW

J Cancer Res Clin Oncol. 2018 Sep 28. doi: 10.1007/s00432-018-2758-6. [Epub ahead of print]
Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X1,2,3, Gu YK1,2,3, Li SL1,2,3, Chen H1,2,4, Chen MS1,2,5, Cai QQ1,2,6, Deng HX1,2,3, Zuo MX7,8,9, Huang JH10,11,12.
Author information

1
    State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, 510060, People's Republic of China.
2
    Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People's Republic of China.
3
    Department of Minimally Invasive Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, People's Republic of China.
4
    Department of Clinical Laboratory, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, People's Republic of China.
5
    Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, People's Republic of China.
6
    Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, People's Republic of China.
7
    State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, 510060, People's Republic of China. [email protected].
8
    Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People's Republic of China. [email protected].
9
    Department of Minimally Invasive Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, People's Republic of China. [email protected].
10
    State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, 510060, People's Republic of China. [email protected].
11
    Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People's Republic of China. [email protected].
12
    Department of Minimally Invasive Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, People's Republic of China. [email protected].

Abstract
PURPOSE:

Anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) therapy has shown promise in tumor immunotherapy. Our objectives were to measure pre-treatment serum-soluble PD-L1 (sPD-L1) levels and to assess the relationships between sPD-L1 levels and clinical characteristics, prognosis, and tumor tissue PD-L1 expression in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC).
METHODS:

Pre-treatment serum sPD-L1 levels were measured with an enzyme-linked immunosorbent assay (ELISA) in 81 patients with HBV-related HCC and compared to those in 49 healthy controls. The association between serum sPD-L1 levels and prognosis was assessed using survival analysis. The correlation between paired serum sPD-L1 levels and tumor PD-L1 expression (in resected tissue homogenates) was assessed in a separate group of 20 patients with HBV-related HCC.
RESULTS:

Median sPD-L1 concentration in patients with HBV-related HCC was 5.129 (range 0.140-12.391) ng/mL and in healthy controls was 0.836 (range 0.105-2.168) ng/mL (p < 0.001). On multivariate analysis, sPD-L1 levels were significant independent predictors of disease-free survival (hazard ratio [HR] 3.503; 95% confidence interval [CI], 1.559-7.871; p = 0.002) and overall survival (HR 3.399; 95% CI 1.308-8.831; p = 0.012). Positive correlation (r = 0.527, p = 0.017) between serum sPD-L1 and tumor PD-L1 expression was observed. Tumor expression of PD-L1 was significantly higher in those with serum sPD-L1 concentrations above vs. below the median level of 5.471 ng/ml (p = 0.012).
CONCLUSIONS:

In patients with HBV-related HCC, serum sPD-L1 concentrations were elevated, and positively correlated with tumor PD-L1 expression. Lower pre-treatment serum sPD-L1 levels were predictors of more favorable disease-free and overall survival. Serum sPD-L1 testing has a potential role in HBV-related HCC disease assessment, systemic therapy choices and survival prediction.
KEYWORDS:

HBV-related hepatocellular carcinoma; Hepatitis B virus; PD-L1; Prognosis; Soluble PD-L1

PMID:
    30267213
DOI:
    10.1007/s00432-018-2758-6

StephenW

J Cancer Res Clin Oncol。 2018年9月28日doi：10.1007 / s00432-018-2758-6。 [提前打印]
可溶性程序性细胞死亡 - 配体1的治疗前血清水平预测乙型肝炎相关肝细胞癌患者的预后。
汉X1,2,3，顾YK1,2,3，李SL1,2,3，陈H1,2,4，陈MS1,2,5，蔡QQ1,2,6，邓HX1,2,3，左MX7,8,9，黄JH10,11,12。
作者信息

1
    中国南方肿瘤学国家重点实验室，中山大学肿瘤防治中心，华南肿瘤学国家重点实验室，广州，510060，中华人民共和国。
2
    中华人民共和国广州市肿瘤医学协同创新中心，510060。
3
    中山大学肿瘤防治中心微创介入放射科，广东广州510060，中华人民共和国。
4
    中山大学肿瘤防治中心临床实验室，广东广州510060，中华人民共和国。
五
    中山大学肿瘤防治中心肝胆外科，广东广州510060，中华人民共和国。
6
    中山大学肿瘤防治中心肿瘤内科，广东广州510060，中华人民共和国。
7
    中国南方肿瘤学国家重点实验室，中山大学肿瘤防治中心，华南肿瘤学国家重点实验室，广州，510060，中华人民共和国。 [email protected]。
8
    中华人民共和国广州市肿瘤医学协同创新中心，510060。 [email protected]。
9
    中山大学肿瘤防治中心微创介入放射科，广东广州510060，中华人民共和国。 [email protected]。
10
    中国南方肿瘤学国家重点实验室，中山大学肿瘤防治中心，华南肿瘤学国家重点实验室，广州，510060，中华人民共和国。 [email protected]。
11
    中华人民共和国广州市肿瘤医学协同创新中心，510060。 [email protected]。
12
    中山大学肿瘤防治中心微创介入放射科，广东广州510060，中华人民共和国。 [email protected]。

抽象
目的：

抗程序性细胞死亡-1（PD-1）/程序性细胞死亡 - 配体1（PD-L1）疗法在肿瘤免疫疗法中显示出前景。我们的目标是测量治疗前血清可溶性PD-L1（sPD-L1）水平，并评估sPD-L1水平与乙型肝炎病毒患者的临床特征，预后和肿瘤组织PD-L1表达之间的关系（ HBV）相关的肝细胞癌（HCC）。
方法：

在81名HBV相关HCC患者中用酶联免疫吸附试验（ELISA）测量治疗前血清sPD-L1水平，并与49名健康对照者进行比较。使用存活分析评估血清sPD-L1水平与预后之间的关联。在20名HBV相关HCC患者的单独组中评估配对血清sPD-L1水平与肿瘤PD-L1表达（在切除的组织匀浆中）之间的相关性。
结果：

HBV相关HCC患者的中位sPD-L1浓度为5.129（范围0.140-12.391）ng / mL，健康对照组为0.836（范围0.105-2.168）ng / mL（p <0.001）。在多变量分析中，sPD-L1水平是无病生存率的显着独立预测因子（风险比[HR] 3.503; 95％置信区间[CI]，1.559-7.871; p = 0.002）和总生存期（HR 3.399; 95％） CI 1.308-8.831; p = 0.012）。观察到血清sPD-L1和肿瘤PD-L1表达之间的正相关（r = 0.527，p = 0.017）。血清sPD-L1浓度高于中位数5.471 ng / ml（p = 0.012）的患者PD-L1的肿瘤表达显着升高。
结论：

在HBV相关HCC患者中，血清sPD-L1浓度升高，与肿瘤PD-L1表达呈正相关。较低的治疗前血清sPD-L1水平是更有利的无疾病和总体存活的预测因子。血清sPD-L1检测在HBV相关的HCC疾病评估，全身治疗选择和生存预测中具有潜在作用。
关键词：

HBV相关的肝细胞癌;乙型肝炎病毒; PD-L1;预后;可溶性PD-L1

结论：
    30267213
DOI：
    10.1007 / s00432-018-2758-6